Canaccord Genuity initiated coverage on Heartflow with a new price target
$HTFL
Medical/Dental Instruments
Health Care
Canaccord Genuity initiated coverage of Heartflow with a rating of Buy and set a new price target of $35.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2025 | $36.00 | Overweight | Analyst |
| 9/2/2025 | $38.00 | Overweight | Piper Sandler |
| 9/2/2025 | $35.00 | Buy | Stifel |
| 9/2/2025 | $35.00 | Buy | Canaccord Genuity |
| 9/2/2025 | $35.00 | Equal-Weight | Morgan Stanley |
MOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), announced the American College of Cardiology (ACC) and the American Heart Association (AHA) published new scientific statements supporting the prognostic value of quantifying coronary plaque and reinforcing the critical role of the coronary computed tomography angiography (CTA) + Heartflow pathway in CAD patient management. The ACC's consensus recommendations, published this week in JACC: Cardiovascular Imaging, highlight the importance of quantitative plaque assessment and underscore the benefits of adopting AI-powered Heartflow
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), announced two new analyses from FISH&CHIPS, a real-world, multicenter, retrospective study of more than 90,000 patients conducted by the National Health Service (NHS) in England, representing the largest fractional flow reserve (FFRCT) study ever conducted. The data, presented today at the European Society of Cardiology's European Association of Cardiovascular Imaging (EACVI) conference in Vienna, provide the strongest real-world evidence to date that Heartflow FFRCT Analysis derived from coronary computed tomography angiography
Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00
Piper Sandler initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00
Stifel initiated coverage of Heartflow with a rating of Buy and set a new price target of $35.00
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
10-Q - Heartflow, Inc. (0001464521) (Filer)
8-K - Heartflow, Inc. (0001464521) (Filer)
SCHEDULE 13G - Heartflow, Inc. (0001464521) (Subject)
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of t